Paradoxical and bimodal immune-mediated dermatological side effects of TNF-α inhibitors: A comprehensive review

被引:1
作者
Behrangi, Elham [1 ,2 ]
Moodi, Farzan [3 ]
Jafarzadeh, Alireza [1 ]
Goodarzi, Azadeh [1 ,2 ,4 ]
机构
[1] Iran Univ Med Sci IUMS, Rasool Akram Med Complex Clin Res Dev Ctr RCRDC, Sch Med, Dept Dermatol, Tehran, Iran
[2] Univ Tehran Med Sci, Skin & Stem Cell Res Ctr, Tehran, Iran
[3] Iran Univ Med Sci, Sch Med, Tehran, Iran
[4] Rasool Akram Med Complex, Dept Dermatol, Niayesh St,Sattarkhan Ave, Tehran, Iran
关键词
eczema; eosinophilic cellulitis; hidradenitis supparativa; paradoxical side effects; psoriasis; sarcoidosis; TNF alpha inhibitors; ANTITUMOR-NECROSIS-FACTOR; STEVENS-JOHNSON SYNDROME; COMPLICATING ADALIMUMAB THERAPY; PYODERMA-GANGRENOSUM; RHEUMATOID-ARTHRITIS; PEMPHIGUS-VULGARIS; WELLS-SYNDROME; DOUBLE-BLIND; NEW-ONSET; ETANERCEPT;
D O I
10.1111/srt.13718
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
IntroductionDue to the increasing prevalence of immune-mediated diseases such as psoriasis, lichen planus, rheumatoid arthritis and inflammatory bowel disease, dermatologists have turned to new biologic drugs known as DMARDs (disease-modifying anti-rheumatic drugs) in recent years.Areas CoveredIn this study, we evaluate the immune-mediated dermatological side effects of DMARDS by reviewing and analyzing previous peer-reviewed research on the effects of TNF-alpha inhibitors in the treatment of skin diseases, as well as adverse effects of these drugs and some of the main causes of these effects.Expert OpinionDMARDs are very effective in improving control of the above diseases. TNF-alpha inhibitors are an important group of DMARDs that are widely used. The paradoxical adverse events (PAEs) associated with the use of TNF-alpha inhibitors are divided into three categories: true paradoxical, borderline paradoxical, and non-paradoxical. True PAEs include conditions for which TNF-alpha inhibitors are approved for treatment. Borderline PAEs are considered to occur with this class of drugs for which there is no definite approval but for which there is sufficient evidence. Although these events are rare, early recognition of the accused drug and appropriate decision-making may prevent progression of complications and irreversible side effects.
引用
收藏
页数:10
相关论文
共 33 条
[31]   Cardiovascular and Venous Thromboembolic Risk With Janus Kinase Inhibitors in Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis of Randomized Trials [J].
Maqsood, Muhammad Haisum ;
Weber, Brittany N. ;
Haberman, Rebecca H. ;
Lo Sicco, Kristen, I ;
Bangalore, Sripal ;
Garshick, Michael S. .
ACR OPEN RHEUMATOLOGY, 2022, 4 (10) :912-922
[32]   Impact of Non-Persistence on Healthcare Resource Utilization and Costs in Patients With Immune-Mediated Rheumatic Diseases Initiating Subcutaneous TNF-Alpha Inhibitors: A Before-and-After Study [J].
Carballo, Nuria ;
Garcia-Alzorriz, Enric ;
Ferrandez, Olivia ;
Navarrete-Rouco, Maria Eugenia ;
Duran-Jorda, Xavier ;
Perez-Garcia, Carolina ;
Monfort, Jordi ;
Cots, Francesc ;
Grau, Santiago .
FRONTIERS IN PHARMACOLOGY, 2021, 12
[33]   Reducing cardiovascular risk in immune-mediated inflammatory diseases: Tumour necrosis factor inhibitors compared to conventional therapies-A systematic review and meta-analysis [J].
Galajda, N. A. ;
Meznerics, F. A. ;
Matrai, P. ;
Fehervari, P. ;
Lengyel, A. S. ;
Kolonics, M. V. ;
Sipos, Z. ;
Kemeny, L. V. ;
Csupor, D. ;
Hegyi, P. ;
Banvolgyi, A. ;
Hollo, P. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 (06) :1070-1088